ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 298.8 USD | -2.33% |
|
+0.62% | -3.91% |
| Jun. 13 | AbbVie inks immune disorder drug licensing deal with China's FutureGen | RE |
| Jun. 10 | Swiss Stocks Flash Red as US Fed Decision Takes Spotlight | MT |
| Sales 2024 * | 60.63B 67.83B | Sales 2025 * | 64.03B 71.64B | Capitalization | 199B 222B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.26B 14.84B | Net income 2025 * | 14.76B 16.51B | EV / Sales 2024 * | 3.51 x |
| Net Debt 2024 * | 13.77B 15.41B | Net Debt 2025 * | 8.84B 9.89B | EV / Sales 2025 * | 3.24 x |
| P/E ratio 2024 * |
14.5
x | P/E ratio 2025 * |
13.1
x | Employees | 103,605 |
| Yield 2024 * |
3.98% | Yield 2025 * |
4.09% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More recommendations
More press releases
| 1 day | -2.33% | ||
| 1 week | +0.62% | ||
| Current month | +12.43% | ||
| 1 month | +15.19% | ||
| 3 months | +7.71% | ||
| 6 months | -6.61% | ||
| Current year | -3.91% |
1 week
295.00
305.99
1 month
261.77305.99
Current year
243.42325.75
1 year
243.42347.50
3 years
243.42473.65
5 years
243.42473.65
10 years
214.46473.65
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 95-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 298.8 | -2.33% | 137 |
| 24-06-10 | 306 | +2.00% | 125 |
| 24-06-07 | 300 | +1.01% | 41 |
| 24-06-06 | 297 | +3.25% | 98 |
Delayed Quote OTC Markets, June 11, 2024 at 01:35 pm EDT
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-06-16
- European Hematology Association Congress
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
245.8
CHF
Average target price
278.1
CHF
Spread / Average Target
+13.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.54% | 781B | |
| -7.20% | 350B | |
| +18.67% | 330B | |
| +7.48% | 293B | |
| +16.91% | 248B | |
| +11.06% | 217B | |
| +3.64% | 162B | |
| -3.96% | 157B | |
| -2.04% | 121B |
- Stock Market
- Equities
- ROG Stock
- RHHBF Stock
